
Researchers found that Paroxetine not only slows down cartilage degeneration, but also promotes cartilage health in both mice and human cartilage in vitro. Credit: Fadia Kamal, Penn State
A disease of the joints, osteoarthritis affects more than 30 million adults and is the fifth-leading cause of disability in the United States. In a new study, scientists have discovered the cellular pathway that leads to osteoarthritis and have identified a commonly used anti-depressant—paroxetine—that inhibits this pathway. The team found that Paroxetine not only slows down cartilage degeneration, but also promotes cartilage health in both mice and human cartilage in vitro. The drug may be the first-ever treatment for this debilitating, degenerative disease.
“Osteoarthritis destroys joint cartilage and results in pain and disability,” said Fadia Kamal, assistant professor of orthopedics and rehabilitation at Penn State College of Medicine. “Patients live with this pain until their cartilage is extremely degenerated. Unfortunately, an invasive artificial joint replacement surgery is the only treatment orthopedists are currently able to offer. There has been a dire need to identify novel therapeutic targets, approaches or agents that can actively halt or reverse the osteoarthritis disease process.”
In previous research, Kamal and her colleagues found that elevated expression and activity of the enzyme G protein-coupled receptor kinase 2 (GRK2) leads to pathologic cell growth in heart and kidney disease.
Kamal explained that osteoarthritis is similarly driven by pathological growth of cartilage cells, a process called chondrocyte hypertrophy, but how this proliferation occurs had been a mystery. Given their knowledge of the role of GRK2 in heart and kidney disease, Kamal and her team decided to investigate the enzyme in osteoarthritis patients. They found that patients with osteoarthritis or acute injury to the joint had high levels of GRK2 in their cartilage cells, or chondrocytes.
“We discovered a central role for GRK2 in cartilage degeneration, where GRK2 pushes chondrocytes to destroy the cartilage matrix surrounding them instead of replenishing and maintaining it.” said Kamal. “In other words, the cells receive a bad signal to destroy cartilage.”
The researchers confirmed the role of GRK2 in cartilage degeneration in two experiments: in one, they performed a genetic deletion of GRK2 from cartilage cells in mice, and in the other, they administered paroxetine—an FDA-approved selective serotonin reuptake inhibitor (SSRI) that is a potent GRK2 inhibitor—to the mice. In both cases, they found that not only did GRK2 deletion prevent chondrocyte hypertrophy and halt osteoarthritis progression, but it also promoted cartilage regeneration.
“We found that paroxetine could return cartilage cells back to a normal state and preserve the cartilage surface,” said Kamal.
In other experiments with cultured human osteoarthritic cartilage, obtained from patients undergoing knee replacement surgery, the team also confirmed the ability of paroxetine to mitigate chondrocyte hypertrophy and cartilage degradation.
The results appear on Feb. 10 in the journal Science Translational Medicine.
“Our findings present elevated GRK2 signaling in chondrocytes as a driver of chondrocyte hypertrophy and cartilage degradation and identify paroxetine as a disease-modifying drug for OA treatment,” said Kamal. “This is important given that around 80% of the U.S. population will develop radiographic evidence of osteoarthritis by age 65 and with the growing prevalence of osteoarthritis risk factors, such as obesity and diabetes, osteoarthritis will likely carry an even greater burden in the future.”
The team is currently seeking approval from the FDA for a new trial of this drug to treat osteoarthritis.
“If this trial works, we will have found a new solution to an age-old problem of joints in the body wearing out because of cartilage destruction and loss,” said Kamal. “We hope to intervene with this disease-modifying treatment for the benefit of our patients.”
Original Article: Common anti-depressant may be first-ever treatment for osteoarthritis
More from: Penn State University College of Medicine
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Paroxetine
- Tramadol for Premature Ejaculation
The forest plot for this analysis is presented in Figure 4. Tramadol vs. Paroxetine (SSRI). The between-group difference in geometric mean IELT (minutes) at 6 weeks, based on one RCT (n = 70 ...
- Psychedelics may better treat depression and anxiety symptoms than antidepressants for patients with advanced cancer
More research is needed on effectiveness of psychedelics to treat anxiety and depression in cancer patients. Exploring psychedelic treatments for patients with other life-threatening diseases that ...
- The Most Common Depression Medications, Explained
Here are some of the most common depression medications: ...
- Paroxetine combination Price of 3 Brands
Details about the Paroxetine combination medication include its price and various forms, such as tablets, capsules, syrups, creams, gels, ointments, liquids, or injections. Click on the brand name ...
- Paroxetine Price of 112 Brands
Details about the Paroxetine medication include its price and various forms, such as tablets, capsules, syrups, creams, gels, ointments, liquids, or injections. Click on the brand name to view the ...
Go deeper with Google Headlines on:
Paroxetine
[google_news title=”” keyword=”paroxetine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Osteoarthritis treatment
- Polymer knee joint ‘could improve quality of life of osteoarthritis patients’
A new kind of artificial knee joint made entirely from polymer could improve the quality of life of people with osteoarthritis who need surgery, scientists have said.The polymer prosthesis, developed ...
- Investigating healthy lifestyle and mortality in osteoarthritis
Healthy lifestyles are thought to reduce mortality in the general population, but it is not known whether the same is true in osteoarthritis. Fan and colleagues present new data on the topic at the ...
- Levolta’s arthritis therapy to be introduced in Middle East
Bethlehem-based Levolta Pharmaceuticals, Inc. has entered into an exclusive licensing and distribution agreement with a Saudia Arabia company for the commercialization of an investigational ...
- Association between healthy lifestyle and mortality in people with osteoarthritis
In this work, data from the UK Biobank were used to investigate the association of both individual and combined healthy lifestyle factors with the risk of all-cause and cause-specific mortality among ...
- What are some home remedies for osteoarthritis?
A doctor can recommend home remedies alongside medical treatments. Read on to find out more about home remedies for osteoarthritis and how they can help. Heat and cold therapy may be beneficial ...
Go deeper with Google Headlines on:
Osteoarthritis treatment
[google_news title=”” keyword=”osteoarthritis treatment” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]









